Answers are grounded in this paper and cite their sources.
The long-term stability of brain–computer interface (BCI) electrodes depends not only on the quality of neural signal acquisition but also on mechanical mismatch at the electrode–neural tissue interface, chronic inflammation, glial scarring, and progressive signal attenuation. Conductive hydrogels combine high water content, low modulus, and favorable interfacial conformity, allowing them to mitigate several limitations of conventional neural electrodes and making them promising materials for BCI electrode design. However, improvements in flexibility and conductivity alone are insufficient to address implantation-induced foreign-body responses. Drug-releasing conductive hydrogels additionally incorporate anti-inflammatory agents, neurotrophic factors, or immunomodulatory molecules into conductive hydrogel networks. While maintaining electrical signal transmission and interfacial conformity, these systems may also modulate local inflammation, glial activation, and neuronal retraction. Existing reviews have largely focused on the functional material design of hydrogel-based BCI interfaces, with limited attention to the regulatory considerations associated with their clinical translation. This review examines the matrix materials, conductive components, and interfacial functionalization strategies of conductive hydrogels, with particular emphasis on drug-delivery approaches and their potential applications in BCI neural electrodes. From a drug–device combination product perspective, we further discuss product classification and biological safety evaluation requirements within the regulatory frameworks of China, the United States, and the European Union, with the aim of informing material development, clinical translation, and science-based regulation.
No takes yet. Share an insight, caveat, or question.
Zang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: